{"id":11341,"date":"2020-07-22T20:07:54","date_gmt":"2020-07-22T18:07:54","guid":{"rendered":"https:\/\/udic.es\/?p=11341"},"modified":"2024-02-14T15:37:40","modified_gmt":"2024-02-14T14:37:40","slug":"fda-aprueba-apomorfina-sublingual-en-bloqueos-off","status":"publish","type":"post","link":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/","title":{"rendered":"FDA autoritza l&#8217;\u00fas d&#8217;apomorfina sublingual en bloquejos off"},"content":{"rendered":"<p>La FDA ha aprovat l&#8217;\u00fas d&#8217;apomorfina sublingual (KYNMOBI) en bloquejos motors, en la malaltia de Parkinson amb fluctuacions motoras.Hem liderat l&#8217;assaig cl\u00ednic a Espanya amb aquest f\u00e0rmac. Els nostres pacients la segueixen fent servir durant la fase oberta d&#8217;extensi\u00f3.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La FDA ha aprovat l&#8217;\u00fas d&#8217;apomorfina sublingual (KYNMOBI) en bloquejos motors, en la malaltia de Parkinson amb fluctuacions motoras.Hem liderat l&#8217;assaig cl\u00ednic a Espanya amb aquest f\u00e0rmac. Els nostres pacients la segueixen fent servir durant la fase oberta d&#8217;extensi\u00f3.<\/p>\n","protected":false},"author":4,"featured_media":9250,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[106],"tags":[],"class_list":["post-11341","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzeimer-ca"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA autoritza l&#039;\u00fas d&#039;apomorfina sublingual en bloquejos off - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"La FDA ha aprovat l&#039;\u00fas d&#039;apomorfina sublingual (KYNMOBI) en bloquejos motors, en la malaltia de Parkinson amb fluctuacions motoras.Hem liderat l&#039;assaig\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA autoritza l&#039;\u00fas d&#039;apomorfina sublingual en bloquejos off - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"La FDA ha aprovat l&#039;\u00fas d&#039;apomorfina sublingual (KYNMOBI) en bloquejos motors, en la malaltia de Parkinson amb fluctuacions motoras.Hem liderat l&#039;assaig\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-22T18:07:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-14T14:37:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"815\" \/>\n\t<meta property=\"og:image:height\" content=\"246\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"SUSANA ANDRADE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"SUSANA ANDRADE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/\"},\"author\":{\"name\":\"SUSANA ANDRADE\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\"},\"headline\":\"FDA autoritza l&#8217;\u00fas d&#8217;apomorfina sublingual en bloquejos off\",\"datePublished\":\"2020-07-22T18:07:54+00:00\",\"dateModified\":\"2024-02-14T14:37:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/\"},\"wordCount\":52,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"articleSection\":[\"Alzeimer\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/\",\"url\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/\",\"name\":\"FDA autoritza l'\u00fas d'apomorfina sublingual en bloquejos off - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"datePublished\":\"2020-07-22T18:07:54+00:00\",\"dateModified\":\"2024-02-14T14:37:40+00:00\",\"description\":\"La FDA ha aprovat l'\u00fas d'apomorfina sublingual (KYNMOBI) en bloquejos motors, en la malaltia de Parkinson amb fluctuacions motoras.Hem liderat l'assaig\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"width\":815,\"height\":246,\"caption\":\"logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA autoritza l&#8217;\u00fas d&#8217;apomorfina sublingual en bloquejos off\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\",\"name\":\"SUSANA ANDRADE\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"caption\":\"SUSANA ANDRADE\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA autoritza l'\u00fas d'apomorfina sublingual en bloquejos off - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"La FDA ha aprovat l'\u00fas d'apomorfina sublingual (KYNMOBI) en bloquejos motors, en la malaltia de Parkinson amb fluctuacions motoras.Hem liderat l'assaig","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/","og_locale":"ca_ES","og_type":"article","og_title":"FDA autoritza l'\u00fas d'apomorfina sublingual en bloquejos off - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"La FDA ha aprovat l'\u00fas d'apomorfina sublingual (KYNMOBI) en bloquejos motors, en la malaltia de Parkinson amb fluctuacions motoras.Hem liderat l'assaig","og_url":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2020-07-22T18:07:54+00:00","article_modified_time":"2024-02-14T14:37:40+00:00","og_image":[{"width":815,"height":246,"url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","type":"image\/png"}],"author":"SUSANA ANDRADE","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"SUSANA ANDRADE","Temps estimat de lectura":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#article","isPartOf":{"@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/"},"author":{"name":"SUSANA ANDRADE","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03"},"headline":"FDA autoritza l&#8217;\u00fas d&#8217;apomorfina sublingual en bloquejos off","datePublished":"2020-07-22T18:07:54+00:00","dateModified":"2024-02-14T14:37:40+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/"},"wordCount":52,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","articleSection":["Alzeimer"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/","url":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/","name":"FDA autoritza l'\u00fas d'apomorfina sublingual en bloquejos off - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","datePublished":"2020-07-22T18:07:54+00:00","dateModified":"2024-02-14T14:37:40+00:00","description":"La FDA ha aprovat l'\u00fas d'apomorfina sublingual (KYNMOBI) en bloquejos motors, en la malaltia de Parkinson amb fluctuacions motoras.Hem liderat l'assaig","breadcrumb":{"@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","width":815,"height":246,"caption":"logo"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/ca\/fda-aprueba-apomorfina-sublingual-en-bloqueos-off\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/ca\/"},{"@type":"ListItem","position":2,"name":"FDA autoritza l&#8217;\u00fas d&#8217;apomorfina sublingual en bloquejos off"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03","name":"SUSANA ANDRADE","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","caption":"SUSANA ANDRADE"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/11341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/comments?post=11341"}],"version-history":[{"count":0,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/posts\/11341\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/media\/9250"}],"wp:attachment":[{"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/media?parent=11341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/categories?post=11341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/ca\/wp-json\/wp\/v2\/tags?post=11341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}